Its core business includes the development of devices for sleep apnea -- such as CPAP and APAP machines -- and digital health solutions. Key success factors for ResMed include maintaining ...

-- The Simple, No-cost Test Can Detect Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Autoantibodies in the Blood with Only a Finger Prick -- The DBS test demonstrates a high ...

ResMed Inc. (NYSE:RMD) Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal ...

ResMed's fifth annual Global Sleep Survey highlights a significant global sleep crisis, revealing that 71% of employed individuals have called in sick at least once due to poor sleep, with the ...